Shares of Vericel (VCEL) surged 5.03% on November 11th, fueled by positive analyst commentary and raised price targets, reflecting strong optimism over the company's growth prospects.
Analysts from Truist Financial and Leerink Partners both reiterated their "Buy" ratings on Vericel, citing the company's promising outlook. Truist Financial raised its price target on the stock to $61 from $57, while Leerink Partners maintained its price target, highlighting the attractive risk/reward profile.
According to analysts polled by Capital IQ, Vericel has an average rating of "Buy" with price targets ranging from $54 to $61. Analysts are bullish on Vericel's potential for continued growth, driven by its innovative products and strong market positioning.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.